• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis.系统性硬化症中间质性肺疾病严重程度的皮肤基因表达相关性
Arthritis Rheum. 2013 Nov;65(11):2917-27. doi: 10.1002/art.38101.
2
A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease.甲磺酸伊马替尼治疗系统性硬化症相关活动性间质性肺病的为期一年的I/IIa期开放标签试点试验。
Arthritis Rheum. 2011 Nov;63(11):3540-6. doi: 10.1002/art.30548.
3
Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score.尼达尼布治疗系统性硬化症相关间质性肺病患者:自身抗体状态和改良 Rodnan 皮肤厚度评分的亚组分析。
Arthritis Rheumatol. 2022 Mar;74(3):518-526. doi: 10.1002/art.41965. Epub 2022 Feb 13.
4
Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial.甲磺酸伊马替尼(格列卫)治疗弥漫性皮肤系统性硬化症:为期 1 年的 IIa 期、单臂、开放性临床试验结果。
Ann Rheum Dis. 2011 Jun;70(6):1003-9. doi: 10.1136/ard.2010.143974. Epub 2011 Mar 11.
5
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.利妥昔单抗治疗系统性硬化症的疗效和安全性:来自欧洲硬皮病试验和研究(EUSTAR)组的分析。
Ann Rheum Dis. 2015 Jun;74(6):1188-94. doi: 10.1136/annrheumdis-2013-204522. Epub 2014 Jan 17.
6
Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease.预测硬皮病相关间质性肺疾病的治疗结果和反应亚组。
Arthritis Rheum. 2011 Sep;63(9):2797-808. doi: 10.1002/art.30438.
7
Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.霉酚酸酯(MMF)治疗肺功能轻度受损的系统性硬化症相关间质性肺病的疗效:一项双盲、安慰剂对照、随机试验。
Rheumatol Int. 2020 Feb;40(2):207-216. doi: 10.1007/s00296-019-04481-8. Epub 2019 Dec 7.
8
CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts.循环中 CCL2 可预测早期系统性硬化症患者间质性肺病的长期进展:来自两个独立队列的数据。
Arthritis Rheumatol. 2017 Sep;69(9):1871-1878. doi: 10.1002/art.40171. Epub 2017 Aug 8.
9
Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort.早期系统性硬化症中肺间质疾病的预测因素:GENISOS 队列的前瞻性纵向研究。
Arthritis Res Ther. 2010;12(5):R166. doi: 10.1186/ar3125. Epub 2010 Sep 2.
10
Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis.皮肤中的分子特征与霉酚酸酯治疗系统性硬皮病时的临床改善相关。
J Invest Dermatol. 2013 Aug;133(8):1979-89. doi: 10.1038/jid.2013.130. Epub 2013 Mar 14.

引用本文的文献

1
ADAM Metallopeptidase domain 19 promotes skin fibrosis in systemic sclerosis via neuregulin-1.ADAM金属蛋白酶结构域19通过神经调节蛋白-1促进系统性硬化症中的皮肤纤维化。
Mol Med. 2024 Dec 23;30(1):269. doi: 10.1186/s10020-024-01047-8.
2
Bacterial Metabolites: A Link between Gut Microbiota and Dermatological Diseases.细菌代谢产物:肠道微生物群与皮肤疾病之间的联系。
Int J Mol Sci. 2023 Feb 9;24(4):3494. doi: 10.3390/ijms24043494.
3
The Molecular Mechanisms of Systemic Sclerosis-Associated Lung Fibrosis.系统性硬皮病相关肺纤维化的分子机制。
Int J Mol Sci. 2023 Feb 3;24(3):2963. doi: 10.3390/ijms24032963.
4
Gut microbe-derived metabolite trimethylamine N-oxide activates PERK to drive fibrogenic mesenchymal differentiation.肠道微生物衍生代谢物氧化三甲胺激活PERK以驱动促纤维化间充质分化。
iScience. 2022 Jun 26;25(7):104669. doi: 10.1016/j.isci.2022.104669. eCollection 2022 Jul 15.
5
Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis.一项抗骨调素 M 单克隆抗体治疗系统性硬化症的随机 2 期研究的生物学和临床见解。
Rheumatology (Oxford). 2022 Dec 23;62(1):234-242. doi: 10.1093/rheumatology/keac300.
6
Genome variation in tick infestation and cryptic divergence in Tunisian indigenous sheep.蜱虫感染的基因组变异和突尼斯本土绵羊的隐性分歧。
BMC Genomics. 2022 Feb 28;23(1):167. doi: 10.1186/s12864-022-08321-1.
7
Multiomic study of skin, peripheral blood, and serum: is serum proteome a reflection of disease process at the end-organ level in systemic sclerosis?皮肤、外周血和血清的多组学研究:血清蛋白质组学是否反映了系统性硬化症终末器官水平的疾病过程?
Arthritis Res Ther. 2021 Oct 15;23(1):259. doi: 10.1186/s13075-021-02633-5.
8
Butyrate Improves Skin/Lung Fibrosis and Intestinal Dysbiosis in Bleomycin-Induced Mouse Models.丁酸盐可改善博来霉素诱导的小鼠模型的皮肤/肺纤维化和肠道菌群失调。
Int J Mol Sci. 2021 Mar 9;22(5):2765. doi: 10.3390/ijms22052765.
9
Biomarkers in systemic sclerosis.系统性硬化症的生物标志物。
Curr Opin Rheumatol. 2019 Nov;31(6):595-602. doi: 10.1097/BOR.0000000000000656.
10
Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature.系统性硬皮病相关间质性肺疾病的生物标志物:文献综述。
Rheumatology (Oxford). 2019 Sep 1;58(9):1534-1546. doi: 10.1093/rheumatology/kez230.

本文引用的文献

1
Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis.皮肤中的分子特征与霉酚酸酯治疗系统性硬皮病时的临床改善相关。
J Invest Dermatol. 2013 Aug;133(8):1979-89. doi: 10.1038/jid.2013.130. Epub 2013 Mar 14.
2
Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets.种间比较人类和小鼠硬皮病揭示 IL-13 和 CCL2 为疾病亚群特异性靶点。
Am J Pathol. 2012 Mar;180(3):1080-1094. doi: 10.1016/j.ajpath.2011.11.024. Epub 2012 Jan 11.
3
A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease.甲磺酸伊马替尼治疗系统性硬化症相关活动性间质性肺病的为期一年的I/IIa期开放标签试点试验。
Arthritis Rheum. 2011 Nov;63(11):3540-6. doi: 10.1002/art.30548.
4
Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension.系统性硬化症患者的肺组织具有肺纤维化和肺动脉高压所特有的基因表达模式。
Arthritis Rheum. 2011 Mar;63(3):783-94. doi: 10.1002/art.30159.
5
Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis.血清趋化因子和细胞因子水平作为系统性硬化症患者疾病活动的指标。
Clin Rheumatol. 2011 Feb;30(2):231-7. doi: 10.1007/s10067-010-1610-4. Epub 2010 Nov 4.
6
Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort.早期系统性硬化症中肺间质疾病的预测因素:GENISOS 队列的前瞻性纵向研究。
Arthritis Res Ther. 2010;12(5):R166. doi: 10.1186/ar3125. Epub 2010 Sep 2.
7
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.系统性硬化症死亡的原因和危险因素:来自 EULAR 硬皮病试验和研究 (EUSTAR) 数据库的研究。
Ann Rheum Dis. 2010 Oct;69(10):1809-15. doi: 10.1136/ard.2009.114264. Epub 2010 Jun 15.
8
A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis.一种四基因生物标志物可预测弥漫性皮肤系统性硬化症患者的皮肤疾病。
Arthritis Rheum. 2010 Feb;62(2):580-8. doi: 10.1002/art.27220.
9
A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity.TGFbeta 反应基因特征与弥漫性硬皮病的一个亚组相关,该亚组疾病严重程度增加。
J Invest Dermatol. 2010 Mar;130(3):694-705. doi: 10.1038/jid.2009.318. Epub 2009 Oct 8.
10
Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials.系统性硬化症临床试验中改良罗德南皮肤厚度评分的变化过程:三项大型多中心、双盲、随机对照试验的分析
Arthritis Rheum. 2009 Aug;60(8):2490-8. doi: 10.1002/art.24681.

系统性硬化症中间质性肺疾病严重程度的皮肤基因表达相关性

Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis.

作者信息

Assassi Shervin, Wu Minghua, Tan Filemon K, Chang Jeffrey, Graham Tiffany A, Furst Daniel E, Khanna Dinesh, Charles Julio, Ferguson Emma C, Feghali-Bostwick Carol, Mayes Maureen D

机构信息

University of Texas Health Science Center at, Houston.

出版信息

Arthritis Rheum. 2013 Nov;65(11):2917-27. doi: 10.1002/art.38101.

DOI:10.1002/art.38101
PMID:23897225
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3898704/
Abstract

OBJECTIVE

We undertook this hypothesis-generating study to identify skin transcripts correlating with severity of interstitial lung disease (ILD) in systemic sclerosis (SSc).

METHODS

Skin biopsy samples from 59 patients enrolled in the Genetics versus Environment in Scleroderma Outcome Study (GENISOS) cohort or an open-label imatinib study (baseline visit) were examined by global gene expression analysis using Illumina HT-12 arrays. Skin transcripts correlating with concomitantly obtained forced vital capacity (FVC) values and the modified Rodnan skin thickness score (MRSS) were identified by quantitative trait analysis. Also, immunofluorescence staining for selected transcripts was performed in affected skin and lung tissue. Plasma levels of CCL2, soluble SELP, and soluble P-selectin glycoprotein ligand 1 (sPSGL-1) were examined in all patients enrolled in the GENISOS cohort (n = 266).

RESULTS

Eighty-two skin transcripts correlated significantly with FVC. This gene list distinguished patients with more severe ILD (FVC <70% predicted) in unsupervised hierarchical clustering analysis (P < 0.001). These genes included SELP, CCL2, and matrix metalloproteinase 3, which are involved in extravasation and adhesion of inflammatory cells. Among the FVC correlates, 8 genes (CCL2, HAPLN3, GPR4, ADCYAP1, WARS, CDC25B, PLP1, and STXBP6) also correlated with the MRSS. Immunofluorescence staining revealed that SELP and CCL2 were also overexpressed in affected skin and lung tissue from SSc patients compared to those from controls. Plasma levels of CCL2 and sPSGL-1 correlated with concomitantly obtained FVC values (r = -0.22, P = 0.001 and r = 0.17, P = 0.015, respectively). This relationship was independent of potential confounders (age, sex, ethnicity, smoking status, anti-topoisomerase I positivity, treatment with immunosuppressive agents, MRSS, disease type, and disease duration).

CONCLUSION

A limited number of skin transcripts including genes involved in extravasation and adhesion of inflammatory cells correlate with severity of ILD.

摘要

目的

我们开展了这项生成假设的研究,以确定与系统性硬化症(SSc)中间质性肺病(ILD)严重程度相关的皮肤转录本。

方法

对参与硬皮病结局研究中的遗传学与环境研究(GENISOS)队列或一项开放标签伊马替尼研究(基线访视)的59例患者的皮肤活检样本,使用Illumina HT - 12芯片通过全基因表达分析进行检测。通过数量性状分析确定与同时获得的用力肺活量(FVC)值和改良Rodnan皮肤厚度评分(MRSS)相关的皮肤转录本。此外,对选定转录本在受累皮肤和肺组织中进行免疫荧光染色。在GENISOS队列的所有患者(n = 266)中检测血浆CCL2、可溶性SELP和可溶性P - 选择素糖蛋白配体1(sPSGL - 1)水平。

结果

82个皮肤转录本与FVC显著相关。在无监督层次聚类分析中,该基因列表区分出ILD更严重(FVC <预测值的70%)的患者(P < 0.001)。这些基因包括SELP、CCL2和基质金属蛋白酶3,它们参与炎症细胞的外渗和黏附。在与FVC相关的基因中,8个基因(CCL2、HAPLN3、GPR4、ADCYAP1、WARS、CDC25B、PLP1和STXBP6)也与MRSS相关。免疫荧光染色显示,与对照组相比,SSc患者受累皮肤和肺组织中SELP和CCL2也过表达。血浆CCL2和sPSGL - 1水平与同时获得的FVC值相关(r = -0.22,P = 0.001和r = 0.17,P = 0.015)。这种关系独立于潜在混杂因素(年龄、性别、种族、吸烟状态、抗拓扑异构酶I阳性、免疫抑制剂治疗、MRSS、疾病类型和病程)。

结论

包括参与炎症细胞外渗和黏附的基因在内的有限数量的皮肤转录本与ILD严重程度相关。